Recent developments in immunotherapy of acute myeloid leukemia

Recent developments in immunotherapy of acute myeloid leukemia

Abstract The advent of new immunotherapeutic agents in clinical practice has revolutionized cancer treatment in the past decade, both in oncology and hematology. The transfer of the immunotherapeutic concepts to the treatment of acute myeloid leukemia (AML) is hampered by various characteristics of...

Full description

Bibliographic Details
Main Authors:	Felix S. Lichtenegger, Christina Krupka, Sascha Haubner, Thomas Köhnke, Marion Subklewe
Format:	Article
Language:	English
Published:	BMC 2017-07-01
Series:	Journal of Hematology & Oncology
Subjects:	AML Antibody therapy Bispecific antibody CAR T cell Checkpoint inhibition Dendritic cell vaccination
Online Access:	http://link.springer.com/article/10.1186/s13045-017-0505-0

Similar Items

New developments in immunotherapy for lymphoma
by: Benjamin Heyman, et al.
Published: (2018-09-01)

Emerging Trends in Immunotherapy for Cancer
by: Alok K. Mishra, et al.
Published: (2022-09-01)

The Role of T Cell Immunotherapy in Acute Myeloid Leukemia
by: Fang Hao, et al.
Published: (2021-12-01)

NK Cell-Based Immunotherapy in Colorectal Cancer
by: Mariella Della Chiesa, et al.
Published: (2022-06-01)

Cancer Immunotherapy: Where Next?
by: Walter Bodmer, et al.
Published: (2023-04-01)

A Clinical Phase 1B Study of the CD3xCD123 Bispecific Antibody APVO436 in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
by: Fatih M. Uckun, et al.
Published: (2021-08-01)

Emerging Immunotherapy Approaches for Treating Prostate Cancer
by: Lingbin Meng, et al.
Published: (2023-09-01)

Immunotherapy Strategy for Systemic Autoimmune Diseases: Betting on CAR-T Cells and Antibodies
by: Vitaly Chasov, et al.
Published: (2024-02-01)

The Latest Breakthroughs in Immunotherapy for Acute Myeloid Leukemia, with a Special Focus on NKG2D Ligands
by: Stefanie Maurer, et al.
Published: (2022-12-01)

Innate Immune Mechanisms and Immunotherapy of Myeloid Malignancies
by: Sara Small, et al.
Published: (2021-11-01)

Current Immunotherapy Approaches in Non-Hodgkin Lymphomas
by: Robert Pytlik, et al.
Published: (2020-11-01)

T-cell Redirecting Therapies for the Treatment of B-cell Lymphomas: Recent Advances
by: Ondine Messéant, et al.
Published: (2021-08-01)

Immunotherapy with Monoclonal Antibodies for Acute Myeloid Leukemia: A Work in Progress
by: Matteo Molica, et al.
Published: (2023-10-01)

Understanding the Spatial Topology of Artificial Immunological Synapses Assembled in T Cell-Redirecting Strategies: A Major Issue in Cancer Immunotherapy
by: Pedro Roda-Navarro, et al.
Published: (2020-01-01)

Emerging Immunotherapy Approaches for Advanced Clear Cell Renal Cell Carcinoma
by: Lingbin Meng, et al.
Published: (2023-12-01)

Immunotherapy as a Turning Point in the Treatment of Acute Myeloid Leukemia
by: Anna Aureli, et al.
Published: (2021-12-01)

CD19-Targeted Immunotherapies for Diffuse Large B-Cell Lymphoma
by: Massimiliano Gambella, et al.
Published: (2022-02-01)

Current status of immunotherapy for non-small cell lung cancer
by: Tao Yang, et al.
Published: (2022-10-01)

The Role of Monoclonal Antibodies in the Era of Bi-Specifics Antibodies and CAR T Cell Therapy in Multiple Myeloma
by: Meera Mohan, et al.
Published: (2021-09-01)

CAR-T cells and BiTEs in solid tumors: challenges and perspectives
by: Julien Edeline, et al.
Published: (2021-04-01)

Overcoming the Hurdles of Autologous T-Cell-Based Therapies in B-Cell Non-Hodgkin Lymphoma
by: Jaco A. C. van Bruggen, et al.
Published: (2020-12-01)

CDX-585, a Bispecific Antibody with Dual Targeting of ILT4 and PD-1 Checkpoint Pathways
by: Michael B. Murphy, et al.
Published: (2023-07-01)

Risk, Characteristics and Biomarkers of Cytokine Release Syndrome in Patients with Relapsed/Refractory AML or MDS Treated with CD3xCD123 Bispecific Antibody APVO436
by: Fatih M. Uckun, et al.
Published: (2021-10-01)

Harnessing Immune Response in Acute Myeloid Leukemia
by: Carola Riva, et al.
Published: (2023-09-01)

CAR T-Cell Therapy Predictive Response Markers in Diffuse Large B-Cell Lymphoma and Therapeutic Options After CART19 Failure
by: Ana Carolina Caballero, et al.
Published: (2022-07-01)

Taking up Cancer Immunotherapy Challenges: Bispecific Antibodies, the Path Forward?
by: Joanie Del Bano, et al.
Published: (2015-12-01)

Identification and Targeting of Mutant Neoantigens in Multiple Myeloma Treatment
by: Valentina Urzì Brancati, et al.
Published: (2023-04-01)

Editorial: New insights into innate immune cell-based immunotherapies in cancer
by: Anne Caignard, et al.
Published: (2024-04-01)

Beyond checkpoint inhibition – Immunotherapeutical strategies in combination with radiation
by: F. Eckert, et al.
Published: (2017-02-01)

Cell‐based and antibody‐mediated immunotherapies directed against leukemic stem cells in acute myeloid leukemia: Perspectives and open issues
by: Peter Valent, et al.
Published: (2020-11-01)

Combination of T cell-redirecting strategies with a bispecific antibody blocking TGF-β and PD-L1 enhances antitumor responses
by: Antonio Tapia-Galisteo, et al.
Published: (2024-12-01)

Current Main Topics in Multiple Myeloma
by: Sonia Morè, et al.
Published: (2023-04-01)

Dissecting the Immune Landscape of Acute Myeloid Leukemia
by: Jan Davidson-Moncada, et al.
Published: (2018-11-01)

Bispecific Antibodies in Hematological Malignancies: A Scoping Review
by: Mohamed H. Omer, et al.
Published: (2023-09-01)

Emerging Immunotherapy for Acute Myeloid Leukemia
by: Rikako Tabata, et al.
Published: (2021-02-01)

Emerging therapies for non-small cell lung cancer
by: Chao Zhang, et al.
Published: (2019-04-01)

Bi- and Tri-Specific T Cell Engager-Armed Oncolytic Viruses: Next-Generation Cancer Immunotherapy
by: Zong Sheng Guo, et al.
Published: (2020-07-01)

Taking the Next Step in Double Refractory Disease: Current and Future Treatment Strategies for Chronic Lymphocytic Leukemia
by: Hayama M, et al.
Published: (2024-03-01)

BCMA-targeted immunotherapy for multiple myeloma
by: Bo Yu, et al.
Published: (2020-09-01)

Monoclonal Antibodies in the Treatment of Diffuse Large B-Cell Lymphoma: Moving beyond Rituximab
by: Sotirios G. Papageorgiou, et al.
Published: (2022-04-01)